About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker INSM · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants Wit…
NCT07234032 · Pulmonary Hypertension, Interstitial Lung Disease
Treprostinil Palmitil Inhalation Powder, Placebo
INSM
Insmed Incorporated
Phase 3Recruiting344Jan 22, 2031Registry ↗
Nov 9, 2026A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Particip…
NCT07765706 · Healthy Volunteers
INS1033, Placebo
INSM
Insmed Incorporated
Phase 1Recruiting116Mar 22, 2027Registry ↗
Nov 9, 2026A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil…
NCT07643155 · Hepatic Impairment
Treprostinil Palmitil Inhalation Powder
INSM
Insmed Incorporated
Phase 1Recruiting30Feb 7, 2027Registry ↗
Nov 4, 2026A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Witho…
NCT06013241 · Chronic Rhinosinusitis Without Nasal Polyps
Brensocatib, Placebo
INSM
Insmed Incorporated
Phase 2Completed288Sep 30, 2025Registry ↗
Nov 2, 2026A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Part…
NCT07805785 · Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Treprostinil Palmitil Inhalation Powder, Placebo
INSM
Insmed Incorporated
Phase 3Recruiting
was not yet recruiting
800Aug 31, 2030Registry ↗
Oct 26, 2026Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pu…
NCT07179380 · Pulmonary Hypertension, Interstitial Lung Disease
Treprostinil Palmitil Inhalation Powder, Placebo
INSM
Insmed Incorporated
Phase 3Recruiting344Dec 30, 2028Registry ↗
Oct 20, 2026An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hyperte…
NCT05649748 · Pulmonary Arterial Hypertension
Treprostinil Palmitil, Placebo
INSM
Insmed Incorporated
Phase 2/3Active, not recruiting91Dec 31, 2026Registry ↗
Oct 16, 2026An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants…
NCT06939647 · Pulmonary Arterial Hypertension, Pulmonary Hypertension, In…
Treprostinil Palmitil
INSM
Insmed Incorporated
—Available——Registry ↗
Oct 13, 2026A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (…
NCT07481981 · Pulmonary Arterial Hypertension
Treprostinil Palmitil Inhalation Powder, Placebo
INSM
Insmed Incorporated
Phase 3Recruiting344Dec 28, 2028Registry ↗
Oct 5, 2026A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK)…
NCT07859007 · Healthy Volunteers
Brensocatib, Midazolam
INSM
Insmed Incorporated
Phase 1Not yet recruiting26Nov 25, 2026Registry ↗
Sep 11, 2026Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
NCT06101823 · Atopic Dermatitis
OpSCF, Placebo
INSM
Insmed Incorporated
Phase 2Completed50Sep 3, 2024Registry ↗
Jun 29, 2026A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Su…
NCT06685835 · Hidradenitis Suppurativa
Brensocatib, Placebo
INSM
Insmed Incorporated
Phase 2Terminated214Feb 12, 2026Registry ↗
Apr 23, 2026An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Ass…
NCT05649722 · Pulmonary Hypertension, Interstitial Lung Disease
Treprostinil Palmitil Inhalation Powder, Placebo
INSM
Insmed Incorporated
Phase 2/3Completed31Apr 1, 2026Registry ↗
Mar 30, 2026A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation P…
NCT05147805 · Pulmonary Arterial Hypertension
Treprostinil Palmitil, Placebo
INSM
Insmed Incorporated
Phase 2Completed102Mar 27, 2025Registry ↗
Mar 12, 2026A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults W…
NCT05090904 · Cystic Fibrosis
Brensocatib, Placebo
INSM
Insmed Incorporated
Phase 2Completed29Nov 1, 2022Registry ↗
Feb 3, 2026Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculou…
NCT04677569 · Mycobacterium Infections, Nontuberculous
ALIS, Azithromycin
INSM
Insmed Incorporated
Phase 3Completed425Nov 21, 2025Registry ↗
Dec 16, 2025A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cy…
NCT04594369 · Non-Cystic Fibrosis Bronchiectasis
Brensocatib 10 mg, Brensocatib 25 mg
INSM
Insmed Incorporated
Phase 3Completed1,767Oct 28, 2024Registry ↗
Nov 21, 2025A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprost…
NCT07102316 · Healthy Volunteers
TPIP F2, TPIP F3
INSM
Insmed Incorporated
Phase 1Completed42Oct 25, 2025Registry ↗
Nov 4, 2025An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiect…
NCT05344508 · Non-Cystic Fibrosis Bronchiectasis
Brensocatib
INSM
Insmed Incorporated
—Approved for marketing——Registry ↗
Mar 17, 2025A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Parti…
NCT05176951 · Pulmonary Hypertension
Treprostinil Palmitil, Placebo
INSM
Insmed Incorporated
Phase 2Completed39Mar 14, 2024Registry ↗
Jun 28, 2024Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial L…
NCT04677543 · Mycobacterium Infections, Nontuberculous
ALIS, Azithromycin
INSM
Insmed Incorporated
Phase 3Completed99May 9, 2023Registry ↗
Jun 13, 2024A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Table…
NCT06344728 · Healthy Participants
Brensocatib Oral Solution, Brensocatib Oral Tablet
INSM
Insmed Incorporated
Phase 1Completed24May 24, 2024Registry ↗
Feb 2, 2024Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Pa…
NCT06238856 · Cystic Fibrosis
SLIT™ Amikacin, Placebo
INSM
Insmed Incorporated
Phase 1Completed18Feb 8, 2005Registry ↗
Jan 22, 2024A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in…
NCT06178783 · Healthy Volunteers
Brensocatib
INSM
Insmed Incorporated
Phase 1Completed20Jan 4, 2024Registry ↗
Jan 5, 2024A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyv…
NCT06193031 · Healthy Volunteers
C16TR, Placebo
INSM
Insmed Incorporated
Phase 1Completed24Dec 18, 2015Registry ↗
Dec 11, 2023A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmaco…
NCT05965570 · Healthy Volunteers
Brensocatib, Clarithromycin
INSM
Insmed Incorporated
Phase 1Completed22Sep 22, 2023Registry ↗
Oct 19, 2023A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalati…
NCT06091579 · Healthy Volunteers
Treprostinil Palmitil Inhalation Powder, Placebo
INSM
Insmed Incorporated
Phase 1Completed42Jan 12, 2021Registry ↗
Sep 22, 2023A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
NCT04791514 · Pulmonary Arterial Hypertension
Treprostinil Palmitil
INSM
Insmed Incorporated
Phase 2Terminated1Aug 26, 2022Registry ↗
Aug 21, 2023A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Partici…
NCT05999942 · Healthy Volunteers
Liposomal Amikacin for Inhalation
INSM
Insmed Incorporated
Phase 1Completed6Jun 29, 2004Registry ↗
Aug 21, 2023A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or…
NCT05826574 · Healthy Volunteers
Brensocatib, Rifampin
INSM
Insmed Incorporated
Phase 1Completed32Jul 16, 2023Registry ↗
Jul 19, 2023A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Partici…
NCT05517525 · Hepatic Impairment
Brensocatib
INSM
Insmed Incorporated
Phase 1Completed30Jun 1, 2023Registry ↗
Jul 3, 2023A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Ca…
NCT05927597 · Healthy Volunteers
INS1007, Placebo
INSM
Insmed Incorporated
Phase 1Completed82Aug 1, 2019Registry ↗
Apr 18, 2023A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal…
NCT05673603 · Renal Impairment
Brensocatib
INSM
Insmed Incorporated
Phase 1Completed28Feb 14, 2023Registry ↗
Mar 27, 2023A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
NCT05355935 · Healthy Volunteer
Brensocatib, Moxifloxacin
INSM
Insmed Incorporated
Phase 1Completed48Oct 7, 2022Registry ↗
Mar 27, 2023Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
NCT03218917 · Non-Cystic Fibrosis Bronchiectasis
Brensocatib 10 mg, Brensocatib 25 mg
INSM
Insmed Incorporated
Phase 2Completed256Dec 12, 2019Registry ↗
Mar 23, 2023A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral A…
NCT05652257 · Healthy Volunteers
[14C]-brensocatib
INSM
Insmed Incorporated
Phase 1Completed7Sep 14, 2021Registry ↗
Jan 6, 2022Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insul…
NCT00577577 · Myotonic Dystrophy Type 1
rhIGF-I/rhIGFBP-3, placebo
INSM
Insmed Incorporated
Phase 2Completed69Dec 29, 2008Registry ↗
Jul 30, 2020Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
NCT03905642 · Cystic Fibrosis
Arikayce™
INSM
Insmed Incorporated
Phase 2Completed49Nov 2, 2010Registry ↗
Jul 30, 2020Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (AR…
NCT00777296 · Cystic Fibrosis
ARIKACE™, Placebo
INSM
Insmed Incorporated
Phase 1/2Completed66Feb 27, 2008Registry ↗
Jun 17, 2020Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic…
NCT01316276 · Cystic Fibrosis
Liposomal amikacin for inhalation
INSM
Insmed Incorporated
Phase 3Completed206Jul 16, 2015Registry ↗
Jun 16, 2020Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
NCT01315678 · Pseudomonas Aeruginosa Infection
Liposomal amikacin for inhalation (Arikayce™) using the PAR…
INSM
Insmed Incorporated
Phase 3Completed302Jun 2013Registry ↗
May 7, 2020Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen A…
NCT02344004 · Mycobacterium Infections, Nontuberculous
LAI (Liposomal Amikacin for Inhalation) 590 mg
INSM
Insmed Incorporated
Phase 3Completed336Jul 3, 2018Registry ↗
Feb 10, 2020Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Particip…
NCT02628600 · NTM Lung Infection Due to MAC
LAI 590 mg, Multi-drug regimen
INSM
Insmed Incorporated
Phase 3Completed163Oct 17, 2018Registry ↗
Aug 21, 2019Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
NCT01315236 · Mycobacterium Infections, Nontuberculous
Liposomal amikacin for inhalation (LAI), placebo
INSM
Insmed Incorporated
Phase 2Completed90Aug 18, 2014Registry ↗
Jul 10, 2019Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chro…
NCT00775138 · Bronchiectasis
280 mg Arikayce™, Matching Placebo for Cohort 1
INSM
Insmed Incorporated
Phase 2Completed64May 11, 2009Registry ↗
Jun 4, 2019Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Ps…
NCT00558844 · Cystic Fibrosis
Arikayce™ 560 mg, Placebo for 560 mg
INSM
Insmed Incorporated
Phase 1/2Completed41Jun 2009Registry ↗
Jul 31, 2018Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
NCT01315691 · Cystic Fibrosis
Liposomal amikacin for inhalation, Placebo for liposomal am…
INSM
Insmed Incorporated
Phase 3Withdrawn0—Registry ↗
Aug 1, 2017Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
NCT00102531 · Osteosarcoma Metastatic
Cisplatin liposomal
INSM
Insmed Incorporated
Phase 1/2Completed19Mar 2008Registry ↗

48 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:18 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances